Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $250.2K in total
- 3
- Insider sellsLast 90 days, $409.9K in total
- 2
- 13F holdersQ2 2026, +29 vs. previous quarter
- 124
- 13F valueReported value at the end of Q2 2026
- $362.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PALI, Q2 2026
No superinvestor reported holding PALI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Palisade Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)6:14 PM ET | Jul 8-9 | 2 days | Baltera Robert Jr.Director | PPurchase | +45.0K | $1.97 | +$88.7K | +10.8%461.9K after | 2 lots |
| Jul 8, 2026 (view filing)6:56 PM ET | Jul 6-7 | 2 days | Baltera Robert Jr.Director | PPurchase | +50.0K | $2.04 | +$102.1K | +13.6%416.9K after | 2 lots |
| Jul 8, 2026 (view filing)6:52 PM ET | Jul 7 | 1 day | Jones Mitchell LawrenceChief Medical Officer | SSale | −51.9K | $2.05 | −$106.5K | −35.6%94.0K after | |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 7 | 1 day | Finley John DavidCEO, CFO | SSale | −146.8K | $2.07 | −$303.3K | −40.3%217.6K after | |
| Jul 6, 2026 (view filing)7:48 PM ET | Jul 1-2 | 5 days | Baltera Robert Jr.Director | PPurchase | +30.0K | $1.98 | +$59.4K | +8.9%366.9K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Jones Mitchell LawrenceChief Medical Officer | SSale | −1.99K | $1.75 | −$3.48K | −13.0%13.3K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Finley John DavidCEO, CFO | SSale | −3.90K | $1.75 | −$6.82K | −12.5%27.4K after | |
| Jan 21, 2026 (view filing) | Jan 16 | 5 days | Williams Donald AllenDirector | PPurchase | +5.00K | $1.67 | +$8.35K | +87.3%10.7K after | |
| Jan 13, 2026 (view filing) | Jan 9 | 4 days | Williams Donald AllenDirector | PPurchase | +5.00K | $1.88 | +$9.40K | +686.8%5.73K after | |
| May 29, 2024 (view filing) | May 28 | 1 day | Williams Donald AllenDirector | PPurchaseComon Stock, par value $0.01 | +1.00K | $4.86 | +$4.86K | New position1.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Palisade Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 13,063,687 | $27.3M | 0.94% | +13,063,687 | New |
| B Group, Inc. | 11,414,285 | $23.9M | 13.54% | 00.0% | Unchanged |
| Ameriprise Financial Inc | 11,081,434 | $23.2M | 0.00% | −428,886−3.7% | Reduced |
| Jupiter Topco LLC | 10,689,452 | $22.4M | 0.01% | +10,689,452 | New |
| BlackRock, Inc. | 10,436,760 | $21.8M | 0.00% | +8,560,420+456.2% | Added |
| Octagon Capital Advisors LP | 10,276,317 | $21.5M | 1.97% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 8,425,065 | $17.6M | 0.27% | −503,084−5.6% | Reduced |
| Ra Capital Management, L.P. | 7,124,116 | $14.9M | 0.13% | 00.0% | Unchanged |
| Franklin Resources Inc | 5,785,189 | $12.1M | 0.00% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 5,253,403 | $11.0M | 0.02% | +4,841,631+1,175.8% | Added |